Table 2 |
||
|
Positivity of nasopharyngeal swabs for influenza virus RNA 6 days after symptom onset according to patient characteristics |
||
|
Variable |
N. of patients positive for viral RNA 6 days after symptom onset/total (%) |
p valuea |
|
|
||
|
Sex |
||
|
Male |
15/21 (71.4) |
|
|
Female |
13/16 (81.3) |
|
|
|
||
|
Immunosuppressionb |
||
|
Present |
6/6 (100) |
|
|
Absent |
22/31 (71) |
|
|
|
||
|
Underlying lung diseasec |
||
|
Present |
7/8 (87.5) |
|
|
Absent |
21/29 (72.4) |
|
|
|
||
|
Any complicationd |
0.005 |
|
|
Present |
17/17 (100) |
|
|
Absent |
11/22 (50) |
|
|
|
||
|
Any complication excluding pneumonia |
||
|
Present |
6/6 (100) |
|
|
Absent |
11/20 (55) |
|
|
|
||
|
Pneumonia |
0.02 |
|
|
Present |
11/11 (100) |
|
|
Absent |
17/26 (65.4) |
|
|
|
||
|
Antiviral treatment |
||
|
Yes |
21/28 (75) |
|
|
No |
7/9 (77.8) |
|
|
|
||
|
Time from symptom onset to initiation of treatment |
||
|
≤ 2 days |
10/15 (66.7) |
|
|
> 2 days |
11/13 (84.6) |
|
|
|
||
|
Antiviral treatment regimene |
||
|
standard |
4/5 (80) |
|
|
intensified |
17/23 (73.9) |
|
|
|
||
|
Antiviral treatment duration |
0.02 |
|
|
≤ 5 days |
3/8 (37.5) |
|
|
> 5 days |
18/20 (90) |
|
|
|
||
|
Antibiotic/antimycotic treatment |
||
|
yes |
18/20 (90) |
|
|
no |
10/17 (58.8) |
|
|
|
||
|
Steroid treatment |
||
|
yes |
4/4 (100) |
|
|
no |
24/33 (72.7) |
|
|
|
||
|
a by chi-square test; p values ≥0.05 have been omitted. b HIV or hairy cells leukaemia. c COPD or Asthma. d Pneumonia, exacerbation of COPD or asthma, petechial rash, elevated ALT. e Standard treatment: oseltamivir 75 mg twice/day; intensified treatment: increased dosage of oseltamivir or oseltamivir+zanamivir. |
||
|
Meschi et al. BMC Infectious Diseases 2011 11:140 doi:10.1186/1471-2334-11-140 |
||
